Wells Fargo raised the firm’s price target on Merck (MRK) to $150 from $135 and keeps an Overweight rating on the shares. The firm thinks Sac-TMT could become the best-in-class TROP2 antibody-drug conjugate and replace chemo in multiple lung, breast, and gynecologic indications.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Portfolio Diversification to Investors
- 3 Best ETFs to Invest In, According to AI Analyst, 03/10/2026
- Controversial Prasad leaving FDA, NYT reports
- Best ETFs to Invest In, According to AI Analyst, 3/4/2026
- Tempus AI, Merck announce AI-driven precision medicine collaboration